Movatterモバイル変換


[0]ホーム

URL:


SG11202010560QA - C26-linked rapamycin analogs as mtor inhibitors - Google Patents

C26-linked rapamycin analogs as mtor inhibitors

Info

Publication number
SG11202010560QA
SG11202010560QASG11202010560QASG11202010560QASG11202010560QASG 11202010560Q ASG11202010560Q ASG 11202010560QASG 11202010560Q ASG11202010560Q ASG 11202010560QASG 11202010560Q ASG11202010560Q ASG 11202010560QASG 11202010560Q ASG11202010560Q ASG 11202010560QA
Authority
SG
Singapore
Prior art keywords
mtor inhibitors
rapamycin analogs
linked rapamycin
linked
analogs
Prior art date
Application number
SG11202010560QA
Inventor
Christopher Michael Semko
Gang Wang
G Leslie Burnett
James Bradley Aggen
Gert Kiss
James Joseph Cregg
Micah James Evans Gliedt
Jennifer Pitzen
Julie Chu-Li Lee
Walter Won
Arun P Thottumkara
Adrian Liam Gill
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines IncfiledCriticalRevolution Medicines Inc
Publication of SG11202010560QApublicationCriticalpatent/SG11202010560QA/en

Links

Classifications

Landscapes

SG11202010560QA2018-05-012019-04-29C26-linked rapamycin analogs as mtor inhibitorsSG11202010560QA (en)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
US201862665426P2018-05-012018-05-01
US201862752881P2018-10-302018-10-30
US201962836040P2019-04-182019-04-18
PCT/US2019/029738WO2019212991A1 (en)2018-05-012019-04-29C26-linked rapamycin analogs as mtor inhibitors

Publications (1)

Publication NumberPublication Date
SG11202010560QAtrue SG11202010560QA (en)2020-11-27

Family

ID=66625253

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11202010560QASG11202010560QA (en)2018-05-012019-04-29C26-linked rapamycin analogs as mtor inhibitors

Country Status (11)

CountryLink
US (2)US11685749B2 (en)
EP (1)EP3788050B1 (en)
JP (1)JP7381492B2 (en)
KR (1)KR20210018243A (en)
CN (1)CN112368289B (en)
AU (2)AU2019262979B2 (en)
CA (1)CA3098698A1 (en)
IL (2)IL278335B2 (en)
MX (2)MX2020011564A (en)
SG (1)SG11202010560QA (en)
WO (1)WO2019212991A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU2017296289A1 (en)2016-07-122019-01-31Revolution Medicines, Inc.2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
AU2018210770B2 (en)2017-01-232022-03-24Revolution Medicines, Inc.Bicyclic compounds as allosteric SHP2 inhibitors
RU2019126455A (en)2017-01-232021-02-24Революшн Медсинз, Инк. PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
SG11202002941WA (en)2017-10-122020-04-29Revolution Medicines IncPyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
BR112020009757A2 (en)2017-12-152020-11-03Revolution Medicines, Inc. polycyclic compounds as allosteric inhibitors of shp2
SG11202010560QA (en)2018-05-012020-11-27Revolution Medicines IncC26-linked rapamycin analogs as mtor inhibitors
LT3788049T (en)2018-05-012023-07-25Revolution Medicines, Inc. C40-, C28-, and C32--LINKED RAPAMYCIN ANALOGUES AS MTOR INHIBITORS
CN113767100A (en)2019-03-012021-12-07锐新医药公司Bicyclic heteroaryl compounds and uses thereof
MX2021010323A (en)2019-03-012021-12-10Revolution Medicines IncBicyclic heterocyclyl compounds and uses thereof.
AU2020377925A1 (en)2019-11-042022-05-05Revolution Medicines, Inc.Ras inhibitors
BR112022008534A2 (en)2019-11-042022-08-09Revolution Medicines Inc COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATE AND METHODS TO TREAT CANCER AND TO TREAT A RAS PROTEIN-RELATED DISORDER
PE20221278A1 (en)2019-11-042022-09-05Revolution Medicines Inc RAS INHIBITORS
CA3156359A1 (en)2019-11-082021-05-14Adrian Liam GillBicyclic heteroaryl compounds and uses thereof
EP4065231A1 (en)2019-11-272022-10-05Revolution Medicines, Inc.Covalent ras inhibitors and uses thereof
IL299131A (en)2020-06-182023-02-01Revolution Medicines IncMethods for delaying, preventing, and treating acquired resistance to ras inhibitors
US20250195521A1 (en)2020-09-032025-06-19Revolution Medicines, Inc.Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en)2020-09-152023-05-01Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
WO2022140427A1 (en)2020-12-222022-06-30Qilu Regor Therapeutics Inc.Sos1 inhibitors and uses thereof
CN113101290A (en)*2021-03-232021-07-13徐州医科大学Application of mTOR inhibitor Torin1 in preparation of cholestatic bile duct injury drug
EP4320101A2 (en)*2021-04-092024-02-14Revolution Medicines, Inc.Synthesis of rapamycin analog compounds
EP4334324A1 (en)2021-05-052024-03-13Revolution Medicines, Inc.Covalent ras inhibitors and uses thereof
CR20230558A (en)2021-05-052024-01-24Revolution Medicines Inc RAS INHIBITORS FOR CANCER TREATMENT
US20230106174A1 (en)2021-05-052023-04-06Revolution Medicines, Inc.Ras inhibitors
AR127308A1 (en)2021-10-082024-01-10Revolution Medicines Inc RAS INHIBITORS
EP4448526A1 (en)2021-12-172024-10-23Genzyme CorporationPyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en)2022-02-112023-08-16Genzyme CorporationPyrazolopyrazine compounds as shp2 inhibitors
CN119136806A (en)2022-03-082024-12-13锐新医药公司 Methods for treating immune-refractory lung cancer
CN119604293A (en)2022-05-252025-03-11锐新医药公司 Methods of treating cancer with mTOR inhibitors
KR20250022133A (en)2022-06-102025-02-14레볼루션 메디슨즈, 인크. macrocyclic RAS inhibitors
US20240124450A1 (en)2022-09-212024-04-18Pfizer Inc.Novel SIK Inhibitors
WO2024206858A1 (en)2023-03-302024-10-03Revolution Medicines, Inc.Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (en)2023-04-072025-06-18Revolution Medicines Inc RAS INHIBITORS
WO2024211712A1 (en)2023-04-072024-10-10Revolution Medicines, Inc.Condensed macrocyclic compounds as ras inhibitors
TW202446388A (en)2023-04-142024-12-01美商銳新醫藥公司Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202448897A (en)2023-04-142024-12-16美商銳新醫藥公司Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202508595A (en)2023-05-042025-03-01美商銳新醫藥公司Combination therapy for a ras related disease or disorder
WO2025034702A1 (en)2023-08-072025-02-13Revolution Medicines, Inc.Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en)2023-10-122025-04-17Revolution Medicines, Inc.Ras inhibitors
WO2025137507A1 (en)2023-12-222025-06-26Regor Pharmaceuticals, Inc.Sos1 inhibitors and uses thereof

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
ZA737247B (en)1972-09-291975-04-30Ayerst Mckenna & HarrisonRapamycin and process of preparation
GB1459571A (en)1974-09-121976-12-22Pfizer LtdThiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus
US4316885A (en)1980-08-251982-02-23Ayerst, Mckenna And Harrison, Inc.Acyl derivatives of rapamycin
US4513135A (en)1982-03-051985-04-23Eli Lilly And CompanyDiaryl-pyrazine derivatives affecting GABA binding
US4911920A (en)1986-07-301990-03-27Alcon Laboratories, Inc.Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (en)1985-10-031988-12-02Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
US4650803A (en)1985-12-061987-03-17University Of KansasProdrugs of rapamycin
JPH0249775A (en)1988-05-191990-02-20Nippon Soda Co LtdHeterocyclic compound having 6-membered or 7-membered ring and production thereof
US5120726A (en)1991-03-081992-06-09American Home Products CorporationRapamycin hydrazones
JPH04230389A (en)1990-07-161992-08-19American Home Prod CorpRapamycin derivative
US5023264A (en)1990-07-161991-06-11American Home Products CorporationRapamycin oximes
US5023263A (en)1990-08-091991-06-11American Home Products Corporation42-oxorapamycin
JPH04112877A (en)1990-09-041992-04-14Nippon Soda Co LtdNew cyanopyrazine derivative and production thereof
PT98990A (en)1990-09-191992-08-31American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
US5221670A (en)1990-09-191993-06-22American Home Products CorporationRapamycin esters
US5130307A (en)1990-09-281992-07-14American Home Products CorporationAminoesters of rapamycin
US5233036A (en)1990-10-161993-08-03American Home Products CorporationRapamycin alkoxyesters
DE69212850T2 (en)1991-01-151997-03-06Alcon Lab Inc Use of carrageenan in topical ophthalmic compositions
GB9103430D0 (en)1991-02-191991-04-03Smithkline Beecham PlcNovel compound
US5212162A (en)1991-03-271993-05-18Alcon Laboratories, Inc.Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5120842A (en)1991-04-011992-06-09American Home Products CorporationSilyl ethers of rapamycin
US5100883A (en)1991-04-081992-03-31American Home Products CorporationFluorinated esters of rapamycin
US5118678A (en)1991-04-171992-06-02American Home Products CorporationCarbamates of rapamycin
US5102876A (en)1991-05-071992-04-07American Home Products CorporationReduction products of rapamycin
US5118677A (en)1991-05-201992-06-02American Home Products CorporationAmide esters of rapamycin
US5162333A (en)1991-09-111992-11-10American Home Products CorporationAminodiesters of rapamycin
US5151413A (en)1991-11-061992-09-29American Home Products CorporationRapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en)1991-12-031992-01-29Smithkline Beecham PlcNovel compound
US5221740A (en)1992-01-161993-06-22American Home Products CorporationOxepane isomers of rapamycin useful as immunosuppressive agents
US5177203A (en)1992-03-051993-01-05American Home Products CorporationRapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
ZA935112B (en)1992-07-171994-02-08Smithkline Beecham CorpRapamycin derivatives
ZA935111B (en)1992-07-171994-02-04Smithkline Beecham CorpRapamycin derivatives
US5256790A (en)1992-08-131993-10-26American Home Products Corporation27-hydroxyrapamycin and derivatives thereof
MX9304868A (en)1992-08-131994-05-31American Home Prod 27-HYDROXYRAPAMICINE, DERIVED FROM THE SAME AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT.
GB9221220D0 (en)1992-10-091992-11-25Sandoz AgOrganic componds
US5489680A (en)1992-10-131996-02-06American Home Products CorporationCarbamates of rapamycin
EP1266900A1 (en)1992-10-132002-12-18WyethCarbamates of rapamycin
US5434260A (en)1992-10-131995-07-18American Home Products CorporationCarbamates of rapamycin
US5411967A (en)1992-10-131995-05-02American Home Products CorporationCarbamates of rapamycin
US5480988A (en)1992-10-131996-01-02American Home Products CorporationCarbamates of rapamycin
US5480989A (en)1992-10-131996-01-02American Home Products CorporationCarbamates of rapamycin
US5302584A (en)1992-10-131994-04-12American Home Products CorporationCarbamates of rapamycin
US5262423A (en)1992-10-291993-11-16American Home Products CorporationRapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5262564A (en)1992-10-301993-11-16Octamer, Inc.Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5258389A (en)1992-11-091993-11-02Merck & Co., Inc.O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en)1992-11-191993-11-09American Home Products CorporationRapamycin carbonate esters as immuno-suppressant agents
US5252579A (en)1993-02-161993-10-12American Home Products CorporationMacrocyclic immunomodulators
US5504091A (en)1993-04-231996-04-02American Home Products CorporationBiotin esters of rapamycin
WO1994025072A1 (en)1993-04-231994-11-10American Home Products CorporationRapamycin conjugates and antibodies
US5387680A (en)1993-08-101995-02-07American Home Products CorporationC-22 ring stabilized rapamycin derivatives
US5378836A (en)1993-10-081995-01-03American Home Products CorporationRapamycin oximes and hydrazones
US5391730A (en)1993-10-081995-02-21American Home Products CorporationPhosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en)1993-10-081994-12-13American Home Products CorporationRapamycin oximes
EP0729471A1 (en)1993-11-191996-09-04Abbott LaboratoriesSemisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en)1993-11-191996-06-18Abbott LaboratoriesMacrolide immunomodulators
US5385909A (en)1993-11-221995-01-31American Home Products CorporationHeterocyclic esters of rapamycin
US5385908A (en)1993-11-221995-01-31American Home Products CorporationHindered esters of rapamycin
US5385910A (en)1993-11-221995-01-31American Home Products CorporationGem-distributed esters of rapamycin
ATE191218T1 (en)1993-12-172000-04-15Novartis Ag RAPAMYCIN DERIVATIVES AS IMMUNOSUPPRESSORS
US5389639A (en)1993-12-291995-02-14American Home Products CompanyAmino alkanoic esters of rapamycin
US5362718A (en)1994-04-181994-11-08American Home Products CorporationRapamycin hydroxyesters
US5463048A (en)1994-06-141995-10-31American Home Products CorporationRapamycin amidino carbamates
US5491231A (en)1994-11-281996-02-13American Home Products CorporationHindered N-oxide esters of rapamycin
US5563145A (en)1994-12-071996-10-08American Home Products CorporationRapamycin 42-oximes and hydroxylamines
US6323201B1 (en)1994-12-292001-11-27The Regents Of The University Of CaliforniaCompounds for inhibition of ceramide-mediated signal transduction
US5741677A (en)1995-06-071998-04-21Geron CorporationMethods for measuring telomere length
CA2219659C (en)1995-06-092008-03-18Novartis AgRapamycin derivatives
US5780462A (en)1995-12-271998-07-14American Home Products CorporationWater soluble rapamycin esters
WO1997048694A1 (en)1996-06-201997-12-24Board Of Regents, The University Of Texas SystemCompounds and methods for providing pharmacologically active preparations and uses thereof
US6342507B1 (en)1997-09-052002-01-29Isotechnika, Inc.Deuterated rapamycin compounds, method and uses thereof
EP1045915A2 (en)1998-01-152000-10-25Ariad Gene Therapeutics, Inc.Regulation of biological events using multimeric chimeric proteins
ES2219388T3 (en)1999-08-242004-12-01Ariad Gene Therapeutics, Inc. 28-EPI-RAPALOGOS.
US6277983B1 (en)2000-09-272001-08-21American Home Products CorporationRegioselective synthesis of rapamycin derivatives
NZ527692A (en)2001-02-192005-05-27Novartis AgCancer treatment
AU2003269949A1 (en)2002-09-122004-04-30Pharmacia & Upjohn Company LlcSubstituted 1,4-pyrazine derivatives
JP2004161716A (en)2002-11-152004-06-10Takeda Chem Ind LtdJnk inhibitor
US7160867B2 (en)2003-05-162007-01-09Isotechnika, Inc.Rapamycin carbohydrate derivatives
US7429596B2 (en)2003-06-202008-09-30The Regents Of The University Of California1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
EP1646635A1 (en)2003-07-162006-04-19WyethCci-779 isomer c
US7220755B2 (en)2003-11-122007-05-22Biosensors International Group, Ltd.42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
EP1571151B1 (en)2004-03-012008-12-24Terumo Kabushiki KaishaProcess for production of O-alkylated rapamycin derivatives
CA2564085C (en)2004-04-302013-04-02Takeda Pharmaceutical Company LimitedHeterocyclic amide compound and use thereof as an mmp-13 inhibitor
CN100516195C (en)2004-07-192009-07-22汕头市双骏生物科技有限公司 A new bacterial strain and the method for producing paclitaxel using the bacterial strain
EP1831225A2 (en)2004-11-192007-09-12The Regents of the University of CaliforniaAnti-inflammatory pyrazolopyrimidines
US20060194829A1 (en)2004-12-202006-08-31Clackson Timothy PTherapeutic materials and methods
US7241771B2 (en)2005-03-072007-07-10WyethOxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
US7189582B2 (en)*2005-04-272007-03-13Dade Behring Inc.Compositions and methods for detection of sirolimus
CA2608715A1 (en)2005-05-202006-09-28Solvay (Societe Anonyme)Method for making a chlorohydrin
US20080288218A1 (en)2005-10-272008-11-20Koninklijke Philips Electronics, N.V.Using Tissue Acceleration to Create Better Dti Waveforms (Doppler Tissue Imaging) for Crt (Cardiac Resynchronization Therapy)
DE602006021608D1 (en)2005-11-172011-06-09Osi Pharm Inc CONDENSED BICYCLIC MTOR INHIBITORS
CA2933875C (en)2005-11-212018-06-26Novartis Ag40-o-(2-hydroxyethyl)-rapamycin for use as a sole drug substance in the treatment of carcinoid tumors arising from the foregut, midgut, or hindgut
GB0525546D0 (en)2005-12-152006-01-25Novartis AgOrganic compounds
KR101499783B1 (en)2006-04-042015-03-09더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Kinase antagonist
US20090274739A1 (en)2006-04-132009-11-05The Trustees Of Columbia University In The City Of New YorkMethods and compositions for treating neointimal hyperplasia
WO2007121453A2 (en)2006-04-172007-10-25The Regents Of The University Of California2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
FR2903038B1 (en)2006-06-292009-04-17Facom Sa SUPPORT FOR A SERIES OF TOOLS.
US7902189B2 (en)2006-08-232011-03-08Astrazeneca AbCompounds
US8492405B2 (en)2006-10-182013-07-23Takeda Pharmaceutical Company LimitedGlucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
EP1916006A1 (en)2006-10-192008-04-30Albert SchömigImplant coated with a wax or a resin
EP2090580B1 (en)2006-11-272014-06-04Terumo Kabushiki KaishaProcess for producing o-alkylated rapamycin derivative, and o-alkylated rapamycin derivative
US20080234262A1 (en)2007-03-212008-09-25WyethPyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
CA2678415A1 (en)2007-04-052008-10-16WyethWortmannin-rapamycin conjugate and uses thereof
JPWO2008156174A1 (en)2007-06-212010-08-26大正製薬株式会社 Pyrazineamide compound
US20090074831A1 (en)2007-09-182009-03-19Robert FaloticoLOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
WO2009046436A1 (en)2007-10-042009-04-09Memorial Sloan-Kettering Cancer CenterMethods for inhibiting senescence of epithelial cells
CN101965335B (en)2008-01-042015-01-14英特利凯恩有限责任公司Certain chemical entities, compositions and methods
US8193182B2 (en)2008-01-042012-06-05Intellikine, Inc.Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US7842475B2 (en)2008-01-082010-11-30Siemens Healthcare Diagnostics Inc.Stabilization of solid support assay reagents
US8993580B2 (en)2008-03-142015-03-31Intellikine LlcBenzothiazole kinase inhibitors and methods of use
US20090253733A1 (en)2008-04-022009-10-08Biointeractions, Ltd.Rapamycin carbonate esters
US20110098241A1 (en)2008-04-142011-04-28Poniard Pharmaceuticals, Inc.Rapamycin analogs as anti-cancer agents
TW200948361A (en)2008-05-262009-12-01Chunghwa Chemical Synthesis & Biotech Co LtdMethod for synthesizing Biolimus A9 and the like and method for improving stability of the same
WO2010006072A2 (en)2008-07-082010-01-14The Regents Of The University Of CaliforniaMtor modulators and uses thereof
NZ590258A (en)2008-07-082013-10-25Intellikine LlcKinase inhibitors and methods of use
US20100055145A1 (en)2008-08-292010-03-04Biosensors International GroupStent coatings for reducing late stent thrombosis
US8703778B2 (en)2008-09-262014-04-22Intellikine LlcHeterocyclic kinase inhibitors
EP2358720B1 (en)2008-10-162016-03-02The Regents of The University of CaliforniaFused ring heteroaryl kinase inhibitors
CN102256966B (en)2008-10-172016-02-10白头生物医学研究所 Soluble mTOR complex and its regulators
US8110578B2 (en)2008-10-272012-02-07Signal Pharmaceuticals, LlcPyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8476282B2 (en)2008-11-032013-07-02Intellikine LlcBenzoxazole kinase inhibitors and methods of use
WO2010059593A1 (en)2008-11-182010-05-27Intellikine, Inc.Methods and compositions for treatment of ophthalmic conditions
EP2427195B1 (en)2009-05-072019-05-01Intellikine, LLCHeterocyclic compounds and uses thereof
EP2435426B8 (en)2009-05-262013-07-03Exelixis, Inc.BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE
TR201900259T4 (en)2009-08-172019-02-21Intellikine Llc Heterocyclic Compounds and Their Uses
MX353747B (en)2009-08-172018-01-26Memorial Sloan Kettering Cancer Center StarHeat shock protein binding compounds, compositions, and methods for making and using same.
WO2011047384A2 (en)2009-10-162011-04-21The Regents Of The University Of CaliforniaMethods of inhibiting ire1
WO2011146882A1 (en)2010-05-212011-11-24Intellikine, Inc.Chemical compounds, compositions and methods for kinase modulation
CN103140494A (en)2010-08-042013-06-05美利奴生命科学有限公司Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties
JP5847386B2 (en)2010-09-152016-01-20関東化學株式会社 Method for producing amine compound
US9079921B2 (en)2010-11-192015-07-14Biocon LimitedProcesses for preparation of Everolimus and intermediates thereof
EP4053133A1 (en)2011-02-042022-09-07Synthon B.V.Process for making trisubstituted silyloxyethyl triflates
AR085397A1 (en)2011-02-232013-09-25Intellikine Inc COMBINATION OF QUINASA INHIBITORS AND THEIR USES
CA2836769C (en)2011-05-042018-11-13Intellikine, LlcThe combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder
CN103796655A (en)2011-05-062014-05-14加利福尼亚大学董事会Treatment of polycystic disease
HK1198579A1 (en)2011-08-102015-04-30Novartis Pharma AgJak p13k/mtor combination therapy
MX370814B (en)2011-09-022020-01-08Univ CaliforniaSubstituted pyrazolo[3,4-d]pyrimidines and uses thereof.
KR20150003156A (en)2012-11-302015-01-08항조우 질록스 파마 컴퍼니 리니티드Rapamycin analogs and methods for making the same
WO2015066371A1 (en)2013-10-312015-05-07Forum Pharmaceuticals, Inc.SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
WO2015095755A1 (en)2013-12-192015-06-25Seattle Genetics, Inc.Methylene carbamate linkers for use with targeted-drug conjugates
CN105461738B (en)2014-06-032019-03-08中国人民解放军军事医学科学院毒物药物研究所 A kind of rapamycin derivative, its preparation method, its pharmaceutical composition and use
KR101668590B1 (en)2014-06-192016-10-25전남대학교병원Bioactive Peptide-coated Stent Promotes Endothelial Cell Proliferation and Prevents Stent Thrombosis
MX2017001981A (en)2014-09-112017-12-12Univ CaliforniamTORC1 INHIBITORS.
WO2016100116A1 (en)2014-12-172016-06-23Siemens Healthcare Diagnostics Inc.Sandwich assay design for small molecules
US20160279108A1 (en)2015-02-242016-09-29University Of KansasTargeted mtor inhibitors
CN106188093B (en)2015-05-082018-06-12上海医药工业研究院A kind of rapamycin structure analog and preparation method thereof
US10683308B2 (en)2015-09-112020-06-16Navitor Pharmaceuticals, Inc.Rapamycin analogs and uses thereof
ES2898882T3 (en)2016-01-112022-03-09Merck Patent Gmbh Quinolin-2-one derivatives
WO2018014858A1 (en)2016-07-212018-01-25正大天晴药业集团股份有限公司M-dihydroxybenzene derivative crystal and salt, and manufacturing method thereof
IL303660A (en)2017-05-022023-08-01Revolution Medicines Inc Rapamycin derivatives as MTOR tracers
UY37900A (en)2017-09-262019-04-30Novartis Ag NEW DERIVATIVES OF RAPAMYCIN
LT3788049T (en)2018-05-012023-07-25Revolution Medicines, Inc. C40-, C28-, and C32--LINKED RAPAMYCIN ANALOGUES AS MTOR INHIBITORS
SG11202010560QA (en)2018-05-012020-11-27Revolution Medicines IncC26-linked rapamycin analogs as mtor inhibitors
KR20210125025A (en)2019-02-072021-10-15베이진 엘티디 Imidazo[2,1-F][1,2,4]triazin-4-amine derivatives as TLR7 agonists
IL299131A (en)2020-06-182023-02-01Revolution Medicines IncMethods for delaying, preventing, and treating acquired resistance to ras inhibitors
EP4320101A2 (en)2021-04-092024-02-14Revolution Medicines, Inc.Synthesis of rapamycin analog compounds
CN119604293A (en)2022-05-252025-03-11锐新医药公司 Methods of treating cancer with mTOR inhibitors

Also Published As

Publication numberPublication date
JP7381492B2 (en)2023-11-15
IL312291A (en)2024-06-01
US20220340596A1 (en)2022-10-27
MX2020011564A (en)2021-01-29
CN112368289B (en)2024-02-20
IL278335B2 (en)2024-09-01
KR20210018243A (en)2021-02-17
EP3788050B1 (en)2024-08-28
CN112368289A (en)2021-02-12
JP2021523113A (en)2021-09-02
AU2019262979B2 (en)2023-07-06
US12187746B2 (en)2025-01-07
WO2019212991A1 (en)2019-11-07
IL278335B1 (en)2024-05-01
US20240166667A1 (en)2024-05-23
US11685749B2 (en)2023-06-27
AU2023241273A1 (en)2023-10-26
CA3098698A1 (en)2019-11-07
IL278335A (en)2020-12-31
EP3788050A1 (en)2021-03-10
AU2019262979A1 (en)2020-12-10
MX2023007581A (en)2023-07-10

Similar Documents

PublicationPublication DateTitle
IL278335A (en)C26-linked rapamycin analogs as mtor inhibitors
SG11202010559UA (en)C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
IL268030B (en)Bicyclic compounds as allosteric shp2 inhibitors
IL275365A (en)6-azaindole compounds
IL289474A (en)Substituted thiazolo-pyridine compounds as malt1 inhibitors
IL275344A (en)4-azaindole compounds
IL287717A (en)Substituted pyrrolopyridines as jak inhibitors
IL279329A (en)Rapamycin analogs and uses thereof
IL275532B1 (en)Mtor inhibitor compounds
LT3898637T (en)Rapamycin derivatives
IL275531A (en)Mtor inhibitor compounds
HK40017118A (en)Rapamycin analogs as mtor inhibitors
HK40095848A (en)C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
HK40052499B (en)C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
HK40039184A (en)Novel mtor inhibitor compounds
IL264465B (en)Substituted thiazolo-pyridine compounds as malt1 inhibitors

[8]ページ先頭

©2009-2025 Movatter.jp